OCUL Form 144: 11,132 Common Shares to Be Sold on NASDAQ
Rhea-AI Filing Summary
Ocular Therapeutix, Inc. filed a Form 144 reporting a proposed sale of 11,132 common shares valued at $137,400.05, with an approximate sale date of 10/08/2025 on NASDAQ. The shares were acquired on 10/07/2025 through restricted stock vesting under a registered plan, and payment (if any) was recorded as Not Applicable. The filing lists 173,995,221 shares outstanding for the issuer. No sales by the reporting person in the prior three months are reported. The filer affirms they are not aware of undisclosed material adverse information and includes broker details for Morgan Stanley Smith Barney LLC.
Positive
- Sale follows documented restricted stock vesting with acquisition dated 10/07/2025
- Broker identified as Morgan Stanley Smith Barney LLC for the planned execution
- No sales in the prior three months are reported for the selling person
Negative
- None.
Insights
TL;DR: This is a routine Rule 144 notice tied to restricted stock vesting with brokered sale planned.
The filing documents a proposed Rule 144 sale of 11,132 vested shares, recorded with Morgan Stanley Smith Barney LLC and an intended execution date of 10/08/2025. The acquisition date is listed as 10/07/2025 and the notice includes the standard attestation about undisclosed material information.
Key procedural dependencies are confirmation of transferability under Rule 144 and timely public disclosure of any material issuer events prior to sale. Watch execution timing and whether any subsequent filings amend the quantity or timing within days of 10/08/2025.
TL;DR: The notice records a single small sale following restricted vesting; no prior three‑month sales reported.
The notice states the shares were issued via restricted stock vesting under a registered plan on 10/07/2025 and the seller plans to offer them through a named broker on 10/08/2025. The filing lists the issuer's outstanding shares as 173,995,221, providing context for the scope of this transaction.
Investor‑relevant items to observe are any follow‑on Form 4 or Form 144 amendments around 10/08/2025 that report execution, and whether multiple insiders file similar notices in the same window.